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Introduction: Evaluation of disease severity in experimental models of rheumatoid arthritis is inevitably associated
with assessment of structural bone damage. A noninvasive imaging technology allowing objective quantification of
pathophysiological alterations of bone structure in rodents could substantially extend the methods used to date in
preclinical arthritis research for staging of autoimmune disease severity or efficacy of therapeutical intervention. Sodium
18 F-fluoride (18 F-NaF) is a bone-seeking tracer well-suited for molecular imaging. Therefore, we systematically examined
the use of 18 F-NaF positron emission tomography/computed tomography (PET/CT) in mice with glucose-6-phosphate
isomerase (G6PI)–induced arthritis for quantification of pathological bone metabolism.
Methods: F-fluoride was injected into mice before disease onset and at various time points of progressing
experimental arthritis. Radioisotope accumulation in joints in the fore- and hindpaws was analyzed by PET
measurements. For validation of bone metabolism quantified by 18 F-fluoride PET, bone surface parameters of
high-resolution μCT measurements were used.
Results: Before clinical arthritis onset, no distinct accumulation of 18 F-fluoride was detectable in the fore- and
hindlimbs of mice immunized with G6PI. In the course of experimental autoimmune disease, 18 F-fluoride bone uptake
was increased at sites of enhanced bone metabolism caused by pathophysiological processes of autoimmune disease.
Moreover, 18 F-fluoride signaling at different stages of G6PI-induced arthritis was significantly correlated with the degree
of bone destruction. CT enabled identification of exact localization of 18 F-fluoride signaling in bone and soft tissue.
Conclusions: The results of this study suggest that small-animal PET/CT using 18 F-fluoride as a tracer is a feasible
method for quantitative assessment of pathophysiological bone metabolism in experimental arthritis. Furthermore, the
possibility to perform repeated noninvasive measurements in vivo allows longitudinal study of therapeutical
intervention monitoring.Introduction
Rheumatoid arthritis (RA) is one of the most common
autoimmune diseases, affecting approximately 1% of the
population in Europe and North America. Bone erosion
can be detected as early as several weeks after the onset
of the first clinical signs and symptoms of RA [1].* Correspondence: ingo.irmler@med.uni-jena.de
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clinical RA; it is characterized by inflammation and
bone destruction. In the past few decades, histopatho-
logical evaluation of joint sections has mainly been used
for assessment of inflammation and bone destruction in
small-rodent models of arthritis. Recently, we showed
the benefit of state-of-the-art imaging modalities for
visualization and quantitative assessment of inflamma-
tion in glucose-6-phosphate isomerase (G6PI)–induced
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CT) [2]. Also, it has been shown that cell proliferation can
be detected in experimental arthritis with the PET prolif-
eration tracer 3′-deoxy-3′-18 F-fluorothymidine [3].
18 F-fluoride not only can be used to label glucose and
other molecules of physiologic relevance but also has fa-
vorable properties in the form of sodium 18 F-fluoride
(18 F-NaF) as a radiotracer per se in noninvasive in vivo
imaging to investigate musculoskeletal diseases [4]. The
use of 18 F-NaF as a bone imaging probe was established
by Blau et al. in the early 1960s [5], but it was subse-
quently replaced by 99mTc-labeled tracers due to their
availability, lower costs and the lower energy of 140-keV
photons, allowing the use of γ-cameras. 18 F-fluoride
PET is an increasingly used molecular imaging modality,
not only in human skeletal disorders but also in small-
animal preclinical research [6-8]. This is facilitated by
the distribution and use of three-dimensional PET scan-
ners with high spatial resolution in clinical medicine and
advantages over 99mTc-labeled bone agents used for skel-
etal scintigraphy, such as higher diagnostic accuracy and
reduced scanning time. Compared to γ-cameras, mo-
lecular imaging using PET provides the advantages of
higher spatial resolution, higher sensitivity and three-
dimensional tomographic image reconstruction. Fur-
thermore, the combination of PET with μCT enables
attenuation correction of radiotracer signaling, allowing
quantitative measurements using 18 F-fluoride PET/CT.
Applied 18 F-NaF, dissociated into Na+ and 18 F−, is rap-
idly cleared from the blood and accumulates in the bone,
where, on the hydroxyapatite surface, an OH− ion is re-
placed by an 18 F− ion to form fluorapatite. The incorpor-
ation of 18 F-fluoride in the bone is determined by vascular
perfusion and bone surface accessible for ion exchange, in-
directly reflecting bone formation and bone resorption [9].
This means that 18 F-NaF can be used not only for the
common measurement of bone mineral deposition but
also for visualization of osteolytic increases of exposed
bone surface, such as in the context of musculoskeletal
autoimmune disease [10].
In clinical oncology, primary bone tumors and skeletal
metastasis can reliably be detected by 18 F-fluoride PET
[4,11]. In mice, pathological osteoblastic activity can be de-
tected even earlier by 18 F-fluoride PET/CT imaging than
by radiography and corresponds to histological evaluation
of increased bone formation [7]. As with bone tumor
pathogenesis, a pathologically increased bone metabolism is
a central feature of chronic arthritis, resulting in functional
disorders of the joints [12]. Therefore, in our present study,
we examined the use of 18 F-NaF small-animal PET/CT for
the quantitative and noninvasive in vivo assessment of
pathophysiological bone metabolism in acute and chronic
stages of experimental G6PI-induced murine arthritis. 18 F-
NaF PET quantification of bone destruction, visible aslesions in cortical bone surface and dysregulated bone for-
mation, was validated using high-resolution CT measure-
ments of the paws.
Methods
Glucose-6-phosphate isomerase–induced arthritis
DBA/1 mice were bred at the animal facility of the Jena
University Hospital (Jena, Germany). All animal studies
were approved by the local commission for animal protec-
tion (Thüringer Landesamt für Verbraucherschutz, Bad
Langensalza, Germany; registered number 02-045/08).
Arthritis was induced as described elsewhere [13]. In brief,
DBA/1 mice were immunized subcutaneously with 400 μg
of recombinant human G6PI in emulsified complete
Freund’s adjuvant (Sigma-Aldrich, Taufkirchen, Germany).
Macroscopic evaluation of arthritis was performed accord-
ing to severity of clinical manifestations in wrist and ankle
joints, in metacarpophalangeal and metatarsophalangeal
joints, and in digits and toes. Swelling and redness in wrist
and ankle joints and in metacarpophalangeal and metatar-
sophalangeal joints, respectively, were graded from 0 to 3.
A score of 0 indicates no macroscopically recognizable
signs of arthritis, 1 indicates swelling and redness, 2 means
strong swelling and redness and 3 indicates massive swell-
ing and redness. Additionally, the number of digits and
toes with inflamed joints were divided in half to avoid as-
sessment imbalance because inflammation in the G6PI-
induced arthritis model is located mainly in proximal
joints of the paws [2]. To calculate the total clinical score
per animal, results from all paws were summed. For PET/
CT measurements, mice were anesthetized with 1.5% to
2% isoflurane (Deltaselect, Dreieich, Germany) vaporized
in oxygen (1.5 L/min) to prevent animal movement and
reduce imaging artifacts. Respiration of mice under
anesthesia was monitored. 18 F-fluoride (half-life = 109 mi-
nutes; Eckert & Ziegler, Bad Berka, Germany) with an ac-
tivity of 10.4 ± 0.8 MBq was injected intravenously into
the lateral tail vein. Longitudinal arthritis imaging was per-
formed at various time points of acute and chronic clinical
arthritis (n = 3 to 6 mice per time point). We obtained dy-
namic PET scans for kinetic analysis of tracer uptake in
nonimmunized mice (n = 3).
Positron emission tomography/computed tomography
in vivo imaging
In vivo 18 F-NaF imaging was performed using a Siemens
Inveon small-animal multimodality PET/CT system (Pre-
clinical Solutions, Siemens Healthcare Molecular Imaging,
Knoxville, TN, USA), characterized by the combination of
two independently operating PETand CT scanners. Radial,
tangential and axial resolutions at the center of the field of
view of the PET module are 1.5 mm for this imaging mo-
dality [14,15]. PET image acquisition was carried out with
a coincidence timing window of 3.4 ns and an energy
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formed for 1,800 seconds, starting 50 minutes after
tracer application. In kinetic analysis, PET data acquisi-
tion lasted 5,400 seconds and started concomitantly
with radiotracer injection. Images were reconstructed into
three-dimensional images using Fourier rebinning and
three-dimensional ordered-subset expectation maximization
algorithm. Attenuation of PET data was corrected based
on the CT measurements. The CT module consists of a
cone-beam X-ray μCT source (50-μm focal spot size) and
a 3,072 × 2,048–pixel X-ray detector. In our μCT imaging
protocol, we used an axial–transaxial resolution of
2,048 × 2,048–pixel, 80 kVp at 500 μA, 360° rotation and
360 projections per bed position for paw measure-
ments and 3,072 × 2,048–pixel, 220° rotation and 120
projections per bed position for whole-animal attenu-
ation scans, respectively. CT images were reconstructed
using a Shepp-Logan filter and cone-beam–filtered
back projection. To reduce stress due to overly pro-
longed measurement times, only high-resolution μCT
data from hindpaws were acquired for correlation ana-
lysis of bone surface assessment with 18 F-fluoride PET
and CT.
Assessment of pathophysiological bone metabolism with
18 F-fluoride or μCT
Quantitative analysis of 18 F-fluoride accumulation in the
period from 50 to 80 minutes after 18 F-fluoride injection
or 0 to 90 minutes, respectively, was enabled by image fu-
sion technology in Siemens Inveon Research Workplace
4.0 software. For dynamic PET analysis, scans were started
5 seconds before radiotracer injection and continued for
90 minutes. The 90-minute data set was divided into 45
time frames (6 × 10 seconds, 6 × 20 seconds, 7 × 60 sec-
onds, 10 × 120 seconds, 10 × 180 seconds and 6 × 300 sec-
onds) during histogramming to construct time–activity
curves. For static analysis, data from 75 to 80 minutes
after 18 F-fluoride injection were analyzed in a single time
frame. Radioisotope activity in the venous blood pool or
in fore- or hindpaws, reflecting bone incorporation of 18 F-
fluoride, was measured as standardized uptake value
(SUV; g/ml) using PMOD 3.15 software (PMOD Technolo-
gies Ltd, Zurich, Switzerland) or Siemens Inveon Research
Workplace 4.0 software. Guided by maximum intensity
projection images, volumes of interest were drawn as
spheres (ellipsoids) over anatomic structures of bones and
joints. A threshold of 40% (max–min) was used to separ-
ate the site of tracer accumulation from background tissue
signaling. Visualization of skeletal elements of the hind-
paws was also done using PMOD 3.15 software.
Analyses of metatarsal CT data were performed using
Definiens Developer XD™ 2.0.3 build 2015 software
(Definiens, Munich, Germany). For segmentation of meta-
tarsal bones, the automatic threshold routine was used.Then, individual bones were discriminated by watershed
segmentation. Oversegmented fragments were merged
manually to achieve three-dimensional objects of each
bone. After identification of metatarsals 1 to 5, a local
threshold was applied on each metatarsal bone to refine
bone margins and remove remaining nonbone pixels. The
threshold was calculated as the difference between mean
pixel gray value and standard deviation of pixel gray
values. Quantitative measurements of bone surface and
bone volume were calculated for each metatarsal bone.
Statistical analysis
Statistical differences between groups were evaluated
using the nonparametric Mann-Whitney U test. Correl-
ation analyses (Spearman test) were performed for PET
data and clinical scoring or PET and CT data, respectively,
whereas CT surface data of all metatarsals, per paw, were
summed. Statistical significance was accepted at P < 0.05
(*P < 0.05, **P < 0.01, ***P < 0.001). In bar charts and text,
data are given as arithmetic means and standard errors of
the mean (SEM). All calculations were performed using
the software package IBM SPSS Statistics version 20.0
(IBM, Ehningen, Germany).
Results
Inflammation and bone destruction in glucose-6-phosphate
isomerase–induced arthritis
Immunization of animals with G6PI induced severe paw
inflammation in DBA/1 mice (Figure 1A). Experimental
disease was characterized by redness and swelling in
wrist and ankle joints, as well as in dorsal areas of the
paws and in metatarsophalangeal, metacarpophalangeal
and phalangeal joints. Macroscopic scoring revealed on-
set of polyarthritis around 9 days after disease induction,
maximum of inflammation at day 14 (d14) and a subse-
quent decrease until d33 (Figure 1B). Histopathology re-
vealed bone erosion in skeletal elements of the inflamed
paws (Figure 1C).
Kinetics of 18 F-fluoride bone uptake in mice
Radiotracer applied intravenously in the tail vein was im-
mediately (0 to 10 seconds postinjection) transported to
the heart via the blood flow (Figure 2A). Subsequent
whole-body distribution of 18 F-fluoride resulted in thoracic
and intestinal PET signaling (10 to 20 seconds postinjec-
tion). After 3 minutes, the pattern of 18 F-fluoride PET sig-
naling indicated onset of bone accumulation, and signaling
from the kidneys and bladder revealed partial radiotracer
excretion. Twenty minutes after radiotracer injection, sig-
naling of nonexcreted 18 F-fluoride was restricted mainly to
bone and continued to increase until the end of measure-
ment at 90 minutes.
Concomitantly, the quantitative time–activity curve ana-
lysis of 18 F-fluoride paw uptake revealed rapid radiotracer
Figure 1 Joint inflammation in glucose-6-phosphate
isomerase–induced arthritis. (A) Photographs showing inflammation
in fore- and hindpaws of arthritic mice (two at right) and nonimmunized
control animals (two at left). (B) Clinical course of inflammatory arthritis
in DBA/1 mice (n= 7). GPI, Glucose-6-phosphate isomerase induction.
(C) Arthritis was associated with destruction of bone. Shown is a
representative image of metatarsal bone revealing cortical bone lesions
(arrows) and infiltration of immune cells to the sites of inflammation. B,
Bone; BM, Bone marrow; J, Joint; CI, Cellular infiltrate; MT, Metatarsal.
Original magnification = 20× (left) and 200× (right).
Figure 2 Biodistribution and bone accumulation of 18 F-fluoride
in naïve mice. (A) Positron emission tomography (PET) scans
(maximum intensity projection) of a naïve mouse after intravenous 18
F-fluoride tail vein injection. Radiotracer was immediately distributed in
the whole organism via the circulation and rapidly accumulated in the
skeletal elements. (B) The 90-minute 18 F-fluoride time–activity curve
reveals rapid 18 F-fluoride clearance from the bloodstream (via the
venae cavae) and subsequent 18 F-fluoride accumulation in the bones
of the fore- and hindpaws. SUV, Standardized uptake value.
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tracer signaling remaining at almost the same level from 40
to 90 minutes postinjection (Figure 2B). At 45 minutes
postinjection, 90% of 18 F-fluoride uptake was achieved
(SUVmean = 1.8), compared to bone radiotracer signaling
after 90 minutes (SUVmean = 1.9). In contrast, blood pool
tracer activity measured in the venae cavae region showed
a rapid decline after an activity maximum (SUVmax = 15.2),
within minutes following injection, reflecting rapid clear-
ance of 18 F-fluoride from the blood.
Localization of exact sites of 18 F-fluoride paw bone uptake
in glucose-6-phosphate isomerase–induced arthritis
Detailed three-dimensional anatomical μCT measure-
ments allowed identification of metatarsal and phalangeal
bones and joints, and PET imaging revealed radiotraceruptake in the paws during the course of experimental
arthritis (Figure 3A). Low 18 F-fluoride accumulation be-
fore immunization switched to a distinct tracer uptake in
the acute (d14) and chronic (d28) stages of disease and de-
clined during late remitting arthritis (d50). Coregistration
of PET and CT data enabled exact localization of 18 F-
fluoride accumulation in arthritic mice.
Detailed, three-dimensional anatomical information
obtained by high-resolution μCT enabled visualization
of the bone surfaces of phalangeal, metatarsal, tarsal
and tibial bones. Compared to nonarthritic control ani-
mals (Figure 3B, left), pathologic bone metabolism in
the mice with G6PI-induced arthritis induced a distinct
increase in bone roughness (Figure 3B, right).
Quantification of pathophysiological bone metabolism
using 18 F-fluoride PET in progressing murine arthritis
To analyze the usability of the 18 F-fluoride PET imaging
modality for quantification of pathological bone metab-
olism in experimental arthritis models, we measured 18
F-fluoride uptake in all paws of mice with G6PI-induced
arthritis at five different time points of disease. Before
onset of clinical arthritis (that is, in bone tissue without
Figure 3 Localization of peripheral 18 F-fluoride accumulation
in glucose-6-phosphate isomerase–induced arthritis. (A) In naive
mice, administration of 18 F-fluoride resulted in low bone tracer
accumulation in the subtalar joints. Under acute arthritic conditions
(day 14 (d14)), there was distinct radiotracer signaling at sites of
manifested disease, whereas increased 18 F-fluoride uptake was
detectable in chronic arthritis (d28). In late remitting arthritis (d50),
18 F-fluoride uptake declined. Shown are representative images of
murine hindpaws obtained with micro–computed tomography
(μCT; top), 18 F-fluoride positron emission tomography (PET; middle)
and coregistered PET and CT (bottom). (B) High-resolution μCT
images of hindpaws obtained before arthritis onset (left) and with
chronic arthritis (right) reveal the impact of inflammatory
autoimmune disease on bone and joint integrity.
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18 F-fluoride accumulation in wrist (Figure 4A) and ankle
(Figure 4B) joints, measured as SUV. In acute clinical
arthritis at d11, paw inflammation was associated with
an increase in bone metabolism and induced a signifi-
cant increase of 18 F-fluoride uptake compared to d8
(P = 0.019 (wrist) and P = 0.002 (ankle)). Mean SUVs at
d8 were 2.08 ± 0.1 in carpal joints and 4.0 ± 0.2 in tarsaljoints, and at d11 mean SUVs were 3.8 ± 0.6 in carpal
joints and 5.8 ± 0.5 in tarsal joints. Mean 18 F-fluoride
uptake was further significantly increased at d18 (4.4 ±
0.5 (carpal) and 6.3 ± 0.5 (tarsal)) and d25 (5.6 ± 0.6 (car-
pal) and 6.5 ± 0.6 (tarsal)), followed by a decrease at d39
(4.4 ± 0.5 (carpal) and 5.0 ± 0.4 (tarsal)). PET data revealed
a 1.3- to 2.8-fold increase in 18 F-fluoride bone uptake
in the paws at progressive stages of inflammatory arth-
ritis, which always differed significantly from 18 F-fluor-
ide accumulation before onset of clinical disease. This
finding indicated a rise of pathological bone-degrading
and bone-forming processes leading to joint dysfunc-
tion, characteristic for RA and its animal models.
To examine the general effects of arthritis on 18 F-fluor-
ide uptake in elements of the skeleton, we quantified PET
signaling in medial and distal femoral bones. SUVs re-
vealed high tracer uptake (SUV > 10) in trabecular distal
areas of the femur (Figure 4C). Except for late remitting
arthritis (d39), SUVs remained at a similar level at differ-
ent stages of G6PI-induced arthritis, indicating only a
slight influence of pathological bone metabolism associ-
ated with arthritis on distal femoral tracer uptake. In con-
trast to trabecular distal areas, mean SUVs in median
cortical areas of the femur ranged from 2.1 to 2.2 in all
stages of arthritis (Figure 4D), additionally negating general
effects of arthritis on bone accumulation of 18 F-fluoride at
sites without clinical manifestations of disease. 18 F-fluoride
PET/CT measurements in healthy mice without any patho-
logical conditions revealed a nonequal pattern of bone
tracer uptake (Additional file 1: Figures S1A and S1B).
There were hotspots of PET signaling in proximal joints of
the pectoral girdle; in the pelvis, including the knees; and in
spinal and cranial bones. Volume-rendering of the knee
joints revealed a coincidence of increased 18 F-fluoride
accumulation and trabecular bone (Additional file 1:
Figure S1C). Therefore, we assume that the increased
surface in trabecular bones, meeting the demands of
distinct mechanical stress or saving weight, is the cause
for the observed heterogeneous pattern of 18 F-fluoride
uptake in skeletal bone.
Quantification of pathophysiological bone metabolism
using μCT
To validate assessment of pathophysiological bone metab-
olism by 18 F-fluoride PET imaging, bone parameters in
μCT data were quantified. Bone surface showed no differ-
ence for metatarsals 1 to 5 between unimmunized mice
and mice with acute inflammatory arthritis (Figure 5A,
d14). In chronic and remitting arthritis (Figure 5A, d28,
d35 and d50), bone surface was significantly increased due
to bone lesions or dysfunctional bone formation. The
course of bone surface assessment was consistent with
the course of SUV data obtained by 18 F-fluoride PET. The
volume of metatarsal bones revealed a slight increase at
Figure 4 Quantification of 18 F-fluoride uptake in progressive arthritis. Pathological effects in arthritic bone metabolism differed from
18 F-fluoride accumulation before clinical arthritis onset can be seen above an arbitrary baseline of 2 and 4 standardized uptake value (SUV) for
fore and hindpaws, respectively. (A) Two days after onset of clinical arthritis at day 9, uptake of 18 F-fluoride in forelimbs was significantly
enhanced (day 11). In chronic arthritis at days 18 and 25, 18 F-fluoride accumulation was further increased significantly compared to day 8,
whereas in late chronic arthritis (day 39), tracer uptake was declining (n = 6 to 12 paws per time point). (B) Hindlimb pathological arthritic bone
metabolism, reflected by 18 F-fluoride signaling in the tarsal joint and metatarsal bones, coincided with forelimb 18 F-fluoride signaling (n = 6 to 12
paws per time point). (C) High-level 18 F-fluoride uptake in distal femoral bone was similar at various time points in the course of arthritis
pathogenesis, except for a significant decrease at day 39. (D) Low-level 18 F-fluoride uptake in medial cortical femoral bone was comparable at
various time points of arthritis pathogenesis. *P < 0.05, **P < 0.01, ***P < 0.001.
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late experimental arthritis at d50 (Figure 5B). Overall, bone
volume was largely unaffected by arthritis pathogenesis.
Regression analysis of clinical parameters and
quantitative PET and CT assessment of bone parameters
To validate quantification of pathological bone metabol-
ism by 18 F-fluoride PET imaging in experimental arthritis,
we performed correlation analysis of quantitative PET re-
sults with semiquantitative clinical scoring data and as-
sessment of bone surface roughness destruction by μCT.
Although inflammation and bone destruction are associ-
ated but functionally not necessarily constrained mecha-
nisms of arthritis pathophysiology, macroscopic clinical
scoring and SUV of 18 F-fluoride were significantly corre-
lated (Figure 6A). More importantly, there was a signifi-
cant correlation of quantitative assessment of pathological
bone metabolism by 18 F-fluoride SUV and assessment ofbone surface by μCT (Figure 6B), demonstrating the
feasibility of these modalities for quantification of bone
destruction in experimental arthritis. Therefore, small-
animal 18 F-fluoride PET/CT is a reliable imaging method
for in vivo quantification of arthritis-induced bone erosion
and bone malformation, correlating with assessment of
pathophysiologic bone surface alterations using μCT.
Discussion
The usefulness of the small-animal PET/CT imaging mo-
dality using 18 F-NaF as a radiotracer is not restricted to the
detection of primary bone tumors and skeletal metastasis
in cancer research. 18 F-fluoride PET/CT imaging is also a
valid technique for use in the assessment of disease severity
according to pathological bone turnover in the field of pre-
clinical arthritis research. In this study, in which we
employed the G6PI-induced arthritis model, we focused on
the feasibility of using 18 F-fluoride PET to visualize and
Figure 5 Quantification bone parameters on high-resolution
μCT images. (A) Quantification of the surface of all five metatarsal
bones (MT1 to MT5) revealed no difference in bone structure
between naïve mice and those with acute arthritis (day 14 (d14)),
when inflammation was at its maximum. In contrast, bone surface
area was significantly increased in chronic arthritis (d28 and d35). In
late chronic arthritis (d50), surface area declined to preinflammation
levels. (B) Volumes of metatarsal bones were almost unaffected by
disease pathogenesis, except for significant increases in MT1, MT4
and MT5 at d28 and significant decreases in MT2 and MT3 at d50
(n = 6 to 12 paws per time point). *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 6 Correlation analysis of arthritis assessment by
18 F-fluoride and μCT imaging. (A) Correlation analysis of
quantitative 18 F-fluoride positron emission tomography/computed
tomography (PET/CT) hindpaw measurements and semiquantitative
macroscopic scoring of paws at different stages of glucose-6-phosphate
isomerase (G6PI)–induced arthritis demonstrated a significant correlation
of both parameters. SUV, Standardized uptake value. (B) Quantitative
assessment of 18 F-fluoride paw uptake PET and the sum of surface of
metatarsal bones 1 to 5 according to μCT data were significantly
correlated (n= 60 paws). *P< 0.05, **P< 0.01, ***P< 0.001.
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arthritic joints noninvasively and in vivo. In addition to
joint inflammation, which can easily be quantified by 18 F-
FDG PET/CT according to activation and proliferation of
resident cells and migrated cells of the immune system,
bone damage is the second major parameter used for as-
sessment of arthritis severity [2].
In contrast to 18 F-FDG, which is trapped in cells at sites
of inflammation due to pathologically increased glucose
metabolism, 18 F-fluoride represents for specific radio-
tracer accumulation in the bone. Erosive processes de-
grading bone and cartilage and dysfunctional bone repair
mechanisms in RA and its animal models are associated
with an increased bone surface. Therefore, the increased
mineral-binding capacity results in site-specific 18 F-fluor-
ide uptake in arthritic joints, which can easily be used for
visualization and, more importantly, provides a measure-
ment method for the quantification of pathological bone
metabolism in preclinical arthritis models. The results of
our studies show increased uptake of 18 F-fluoride in the
paws of arthritic mice and reveal that the 18 F-fluoride
PET/CT quantification of pathologic bone metabolism in
arthritis pathogenesis significantly correlated with ourassessment of pathophysiologic bone surface alterations
based on high-resolution μCT measurements.
Radioisotope imaging is, to date, one of the most ap-
plicable imaging modalities for functional and whole-
body in vivo quantification of bone metabolism in mice.
Compared to other radiopharmaceuticals used for bone
imaging, such as 99mTc, 18 F-fluoride has some beneficial
attributes. First, 18 F-fluoride has a high affinity to bone,
resulting in favorable skeletal kinetics. Within 60 minutes
after intravenous injection, only 10% of the injected dose
is still located in the bloodstream [10]. Thus the concur-
rence of rapid bone uptake and fast blood-pool clearance
yields a favorable bone-to-background ratio. Addition-
ally, 18 F-fluoride does not accumulate in inflamed soft
tissue and only minimally binds to serum proteins [16].
Furthermore, small-animal 18 F-NaF PET measurements
have an excellent reproducibility in animal models of
bone disease [6,17].
One limiting factor in 18 F-fluoride PET imaging might
be vascularization of the tissue restricting tracer delivery.
In contrast to epithelial tissue, the circulation in well-
vascularized bone tissue is less affected by exogenous
factors, allowing reproducible data acquisition. In experi-
mental arthritis, the increased vascularization and blood
flow in inflamed tissue may influence tracer delivery and,
therefore, PET signaling at stages of acute inflammation.
Nevertheless, at time points of maximal tracer uptake in
our experiments, clinical arthritis was already remitting
and macroscopically visible signs of inflammation were di-
minished. Another important aspect of 18 F-fluoride PET
imaging is bone structure. Skeletal elements consisting of
cortical and trabecular bone result in strong baseline PET
signaling. This is presumably caused by the manifold in-
crease in bone surface and less by increased metabolism at
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bone are only slightly different. However, both decrease
significantly if bone matrix is demineralized [18]. There-
fore, if bones with cancellous and noncancellous struc-
tures are located near regions of interest, data analyses
require a high degree of anatomical accuracy, which can
be achieved with μCT. In quantification of experimental
arthritis severity, we found that the effect of high baseline
signaling in tibial and radial bones was of negligible rele-
vance for 18 F-fluoride PET imaging, because signaling
hotspots of arthritis pathogenesis were located in tarsal,
metatarsal and carpal and metacarpal bones. Another
source of a high and pathological 18 F-fluoride baseline
PET signaling independent of autoimmune disease patho-
genesis might be the preoccurrence of osteoarthritis
resulting in mechanical bone erosion. Whereas this aspect
is not relevant for imaging in experimental arthritis
models, it should be considered in RA bone imaging,
where age is a risk factor.
Conclusion
In our present study, we demonstrate the capability of 18 F-
fluoride PET to monitor and quantify pathological bone
conditions in the model of G6PI-induced arthritis. Further-
more, we validated this bone imaging technique success-
fully by using bone surface μCT data. Because 18 F-fluoride
PET is a noninvasive and nondestructive way to measure
bone metabolism in vivo, this molecular imaging modality
is not only useful for numerous applications in basic animal
science, where pathophysiological bone metabolism is of
interest, but also is a valuable tool for use in preclinical
arthritis research, where pathological bone destruction and
inflammation are the major parameter used for assessment
of disease severity.Additional file
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